60 filings
8-K
CABA
Cabaletta Bio Inc
21 Mar 24
Cabaletta Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
7:12am
8-K
CABA
Cabaletta Bio Inc
20 Mar 24
Cabaletta Bio Announces FDA Granted Orphan Drug Designation to CABA-201 for Treatment of Systemic Sclerosis
7:11am
8-K
CABA
Cabaletta Bio Inc
1 Feb 24
Cabaletta Bio Announces FDA Granted Orphan Drug Designation to CABA-201 for Treatment of Myositis
4:36pm
8-K
CABA
Cabaletta Bio Inc
8 Jan 24
Results of Operations and Financial Condition
7:11am
8-K
CABA
Cabaletta Bio Inc
9 Nov 23
Cabaletta Bio Reports Third Quarter 2023 Financial Results and Provides Business Update
7:12am
8-K
tzx6s v8gtn9
6 Nov 23
Cabaletta Bio Receives FDA Clearance of CABA-201 IND Application for Treatment of Generalized Myasthenia Gravis
7:03am
8-K
qx4ikrrt
2 Oct 23
Regulation FD Disclosure
7:38am
8-K
bazjc
5 Sep 23
Regulation FD Disclosure
8:45am
8-K
no49953dflq0l
22 Aug 23
Cabaletta Bio and WuXi Advanced Therapies Announce Expansion of GMP Manufacturing Agreement to Include CABA-201
8:03am
8-K
rop62 pqzj
10 Aug 23
Cabaletta Bio Reports Second Quarter 2023 Financial
7:16am
8-K
mtr4tm
24 Jul 23
Cabaletta Bio Appoints Global Commercial Leader Shawn Tomasello to Board of Directors
8:06am
8-K
v3gsgq09zv9 kpx36pm
1 Jun 23
Departure of Directors or Certain Officers
4:05pm
8-K
z0x2ccunaf5cz mo
22 May 23
Cabaletta Bio Announces Closing of $100 Million Public Offering of Common Stock, Including Full Exercise of Option to Purchase Additional Shares
4:35pm
8-K
iq68j1 1942q1cj
18 May 23
Cabaletta Bio Announces Pricing of Public Offering of Common Stock
4:33pm
8-K
kxtlj hr95jm06n3gr
16 May 23
Regulation FD Disclosure
4:01pm
8-K
cbtgbj18ce pxkqi4tj
16 May 23
Cabaletta Bio Receives FDA Clearance of IND Application for CABA-201 for Treatment of Myositis
7:04am
8-K
zswndjj1iw v5x5
11 May 23
Cabaletta Bio Reports First Quarter 2023 Financial Results and Provides Business Update
7:05am
8-K
xnzqsmn61w
2 May 23
Cabaletta Bio to Present at the American Society of Gene and Cell Therapy 26th Annual Meeting
4:39pm
8-K
f3wpovqb8dplpyvz5jf
1 May 23
Regulation FD Disclosure
7:17am
8-K
vo5t6s6 07
31 Mar 23
Regulation FD Disclosure
7:14am